Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

 Blogroll
Interim Analysis Of 12-Month Data From E-HEALING Registry Shows Good Safety And Efficacy In Real-World Use Of OrbusNeich's Genou

Interim Analysis Of 12-Month Data From E-HEALING Registry Shows Good Safety And Efficacy In Real-World Use Of OrbusNeich's Genou

Oct 14 2008 | comment(s)

WASHINGTON, October 14 /PRNewswire/ --

- Additional Data Presentation Shows Encouraging 12-Month Outcomes from Single-Center Study Involving Patients with Predominantly Complex Lesions

OrbusNeich today announced that an interim analysis of 12-month follow-up data from the global e-HEALING registry show good safety and efficacy in the real-world use of the company's Genous Bio-engineered R stent.

Atmel, Cisco And The Swedish Institute Of Computer Science (SICS) Collaborate To Support A Future Where Any Device Can Be Connec

Atmel, Cisco And The Swedish Institute Of Computer Science (SICS) Collaborate To Support A Future Where Any Device Can Be Connec

Oct 14 2008 | comment(s)

SAN JOSE, California and BANGALORE, India, October 14 /PRNewswire/ --

- One of the World's Smallest Open-Source, IPv6-Ready Protocol Stack Enables Cost-Effective Deployment of Sensor-Based 'Smart' Objects

Atmel(R) Corporation (Nasdaq: ATML), Cisco and the Swedish Institute of Computer Science (SICS) today announced the availability of uIPv6, one of the world's smallest open-source, IPv6-ready protocol stack, which could enable every device, no matter how limited by power or memory to have an Internet Protocol address.

Novel Solid-State Laser Design Based On Synthetic Diamond From Element Six Opens Up New Applications

Novel Solid-State Laser Design Based On Synthetic Diamond From Element Six Opens Up New Applications

Oct 14 2008 | comment(s)

ASCOT, England, October 14 /PRNewswire/ -- Researchers at the Institute of Photonics, University of Strathclyde, have started work on a 3.5 year project to develop a novel solid-state laser design incorporating CVD (chemical vapour deposition) diamond manufactured by Element Six Ltd. Element Six leads the world in the field of CVD diamond synthesis and its application.

Baxa Ltd Launches ZR(R) Pre-Filled Saline Flush Syringes

Baxa Ltd Launches ZR(R) Pre-Filled Saline Flush Syringes

Oct 14 2008 | comment(s)

BRACKNELL, England, October 14 /PRNewswire/ --

- Baxa introduces new line of sterile, pre-filled saline syringes for safe and efficient flushing of IV lines. The ZR syringes meet NHS standards and promote best practice for catheter care.

Topcomm Shows XLN Telecom Ranks Above The Competition

Topcomm Shows XLN Telecom Ranks Above The Competition

Oct 14 2008 | comment(s)

LONDON, October 14 /PRNewswire/ -- XLN Telecom - the UK's leading telecoms company serving the small business community - has been ranked above both BT and TalkTalk by Topcomm. Topcomm measures key performance indicators such as delivering on-time orders, providing accurate billing and promptly handling and resolving complaints and faults.

Michael J. Fox Foundation Awards $2 Million Grant From Merck Serono To Research Projects On Cognitive Deficits In Parkinson's Di

Michael J. Fox Foundation Awards $2 Million Grant From Merck Serono To Research Projects On Cognitive Deficits In Parkinson's Di

Oct 14 2008 | comment(s)

GENEVA, Switzerland, October 14 /PRNewswire/ --

- Five Research Teams Selected to Receive Funding for Preclinical and Clinical Research Projects in Parkinson's Disease-Related Cognitive Deficits and Mood Disorders

The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded a total of $2 million to five research teams to speed development of effective therapies for the under-addressed cognitive and mood-related symptoms of Parkinson's disease (PD). The award was made possible by leadership funding from Merck Serono, a division of Merck KGaA, Darmstadt, Germany.